Search

A 53-year-old man developed pericardial effusion and pericarditis while being treated with minoxidil for androgenetic alopecia. He had a history of well-controlled type 2 diabetes and started minoxidil treatment. After 20 days, he was hospitalized due to a large pericardial effusion and later diagnosed with pericarditis. Minoxidil was considered the likely cause after ruling out other potential reasons. The man's treatment was stopped, and follow-up tests showed resolution of the pericardial issues with no signs of recurrence. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA male patient [age not stated] developed cutis verticis gyrata during treatment with minoxidil for androgenetic alopecia [dosage, duration of treatment to reaction onset and outcome not stated].The male patient who, had androgenetic alopecia, started receiving treatment with topical minoxidil. However, after long-term use he developed cutis verticis gyrata secondary to minoxidil therapy. [Extracted from the article]

In a retrospective cohort study, six patients with cystic fibrosis developed alopecia while receiving therapy with elexacaftor/ivacaftor/tezacaftor. The patients had a history of cystic fibrosis and received either Trikafta or lexacaftor/ivacaftor/tezacaftor. The duration of alopecia ranged from 6 to 24 months from the start of therapy. Laboratory findings showed low iron levels, low ferritin, high prothrombin time, high transferrin, and one patient tested positive for COVID-19. Treatment with biotin, oral contraceptives, minoxidil, spironolactone, iron supplements, and OTC hair supplements improved alopecia in five patients, but one patient did not respond to iron supplements, indicating lack of efficacy. [Extracted from the article]

A case report published in Reactions Weekly describes a 51-year-old man who experienced vasodilatory shock and EKG changes after accidentally drinking topical minoxidil, a medication used to treat hypertension. The man presented with chest pressure, shortness of breath, and lightheadedness. In the emergency room, he was found to be tachycardic, tachypneic, and hypotensive, with abnormal EKG findings. He was admitted to the cardiac intensive care unit and treated with medications to stabilize his blood pressure. The patient's condition improved, and he was discharged home with a stable condition. [Extracted from the article]

A case report published in Reactions Weekly describes a man in his late 60s who experienced lack of efficacy while being treated with minoxidil and unspecified dihydropyridines for hypertension. The patient, who was on hemodialysis, presented with fluid overload and high levels of potassium. Despite receiving treatment with beta-adrenergic-receptor-agonists, dihydropyridines, and minoxidil, his hypertension and fluid overload persisted. However, after receiving enemas and oral castor oil, his blood pressure and volume status improved, and his potassium levels decreased. The patient resumed hemodialysis after nine days. [Extracted from the article]

A 34-year-old woman experienced central retinal vein occlusion (CRVO) while being treated with minoxidil for hair loss. The woman presented with nonischemic CRVO in her right eye, with minimal cystoid macular edema. She had been taking oral minoxidil 0.5mg nightly for a year and had no other risk factors. The CRVO was attributed to minoxidil, and her treatment was stopped. Her macular edema worsened initially but gradually improved, and complete resolution of the CRVO was observed with a return to normal visual activity. [Extracted from the article]

A 73-year-old woman experienced serotonin syndrome (SS) due to the interaction of erythromycin, venlafaxine, and escitalopram. She also had a lack of efficacy with multiple medications for arterial hypertension, including clonidine, labetalol, metoprolol, furosemide, midazolam, morphine, amlodipine, and minoxidil. Additionally, she developed a rebound effect of worsening arterial hypertension while taking cyproheptadine. Despite treatment, her blood pressure remained high, and she eventually died from ventricular fibrillation, cardiac arrest, myocardial infarction, myeloma kidney, SS, and arterial hypertension. [Extracted from the article]

A woman in her early 20s experienced treatment failure with multiple drugs while being treated for alopecia areata. She had received various treatments including clobetasol, finasteride, minoxidil, and unspecified corticosteroids, but did not see any improvement and her condition worsened. She was then diagnosed with alopecia areata and started receiving tofacitinib, which resulted in significant improvement and regrowth of hair. She continued to be maintained on tofacitinib without any further alopecia. [Extracted from the article]

A 31-year-old man experienced ophthalmic hypertension while being treated with minoxidil for androgenic alopecia. He presented with symptoms of diplopia and increased intraocular pressure. It was determined that the ophthalmic hypertension was a result of the minoxidil treatment. The man's condition improved after discontinuing minoxidil and receiving other topical therapies. After 10 months of follow-up, there were no signs of progression and his condition was gradually improving. [Extracted from the article]

This document provides a list of drugs associated with non-serious adverse events identified in the scientific literature over the last week. The table includes the drug names, the adverse events, and the number of cases reported. Some of the drugs mentioned include Abemaciclib, Letrozole, Minoxidil, Ribociclib, Alcohol, Apremilast, Aripiprazole, Aspirin, and many others. The adverse events range from alopecia and musculoskeletal disorders to diarrhoea and lack of efficacy in critical conditions. It is important to note that this information is based on case reports and should be interpreted with caution. [Extracted from the article]

A retrospective study examined the adverse effects of minoxidil treatment in patients with hypertension and hair loss. The study included six patients who experienced intense hair shedding, fluid retention, lightheadedness, general malaise, tachycardia, or hypertrichosis while taking minoxidil. The patients initially started on a low dose of oral minoxidil but discontinued treatment due to these adverse effects. One patient briefly restarted treatment but stopped again due to hypertrichosis. [Extracted from the article]

A 50-year-old woman with alopecia universalis (AU) experienced a lack of efficacy with various treatments, including minoxidil, ciclosporin, and corticosteroids. Despite trying different combinations of topical, intralesional, and systemic corticosteroids, as well as minoxidil, the patient did not see any improvement in her condition. She also developed patches of vitiligo on her scalp. After switching to risankizumab and then deucravacitinib, the patient experienced rapid hair regrowth on her eyebrows, eyelashes, body hair, and scalp. At a follow-up visit, moderate regrowth of dark hair was observed on her legs, eyelashes, eyebrows, and arms. [Extracted from the article]

A 65-year-old man experienced acute pleuro-pericarditis with pleuro-pericardial effusion while being treated with minoxidil for hypertension. The man had a medical history of hyperlipidemia, hypertension, gout, and type 2 diabetes mellitus. He presented with symptoms such as shortness of breath, chest pain, and dizziness. After discontinuing minoxidil and receiving treatment with colchicine and ibuprofen, the patient experienced mild improvement and eventually recovered with no recurrence of symptoms. [Extracted from the article]

A 73-year-old man developed pulmonary hypertension (PH) while being treated with minoxidil. The man had type 2 diabetes, chronic kidney disease, and chronic obstructive pulmonary disease. He presented with symptoms such as difficulty breathing and low oxygen levels, and tests revealed severe PH. The man was treated in the intensive care unit and eventually recovered, but his minoxidil treatment was permanently discontinued. The article suggests that the man's PH was a result of minoxidil use. [Extracted from the article]

A 46-year-old man experienced pericardial effusion while being treated with minoxidil for resistant hypertension. The man had type 1 diabetes and had undergone a renal transplant. He was taking multiple medications for his hypertension. He was admitted to the cardiology department multiple times due to symptoms such as dyspnea and palpitations. A large pericardial effusion was observed, and the fluid was drained through pericardiocentesis. The analysis of the fluid showed no signs of infection, malignancy, or inflammation. The man's minoxidil treatment was discontinued, and a month later, a follow-up echocardiography showed complete resolution of the pericardial effusion. [Extracted from the article]

Two case studies were conducted on teenage girls with alopecia who received biotin treatment. In both cases, the girls did not experience any improvement in their condition, suggesting that biotin was not effective. Alternative treatments, such as ferrous sulfate+ferrous-gluconate, spironolactone, and combination foam, as well as platelet-rich plasma, were used and resulted in improved hair density for both girls. The second girl also reported hair growth and less thinning after platelet-rich plasma treatment. [Extracted from the article]

A 37-year-old woman experienced shock after a dispensing error with minoxidil, a medication for hair loss. She developed severe vomiting, diarrhea, and dizziness shortly after taking the first dose. Upon admission to the emergency department, her vital signs were unstable, and laboratory tests showed abnormalities. It was discovered that the pharmacist had dispensed minoxidil instead of the intended medication, Minoxidin. The woman received treatment and her symptoms resolved. This incident highlights the potential dangers of medication errors and the importance of accurate prescription filling. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 59-year-old man developed drug induced lupus erythematosus (DILE) during treatment with minoxidil for hypertension [route, dosage, duration of treatment to reactions onset and final outcome of ADR not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 55-year-old man developed drug-induced lung disease (DILD) and cellular non-specific interstitial pneumonia (NSIP) with granulomatous inflammation following intentional misuse of minoxidil. [Extracted from the article]

A case report discusses the treatment of a girl with alopecia universalis (AU), a condition characterized by complete hair loss on the scalp and body. The girl initially received topical treatments with minoxidil and mometasone, but experienced no improvement. She then underwent treatment with diphencyprone and narrow band ultraviolet B (NB UVB) phototherapy, which resulted in partial hair regrowth. However, after experiencing severe stress, she had another episode of AU and was treated with oral upadacitinib, an off-label treatment for AU. This treatment led to significant improvement in both AU and atopic dermatitis (AD), but also caused transient mild leukopenia. Despite this side effect, the upadacitinib therapy was continued. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 18-year-old man developed refractory shock, giddiness, vomiting, cardiac failure, drowsiness, hypotension, bilateral crackles, tachypnoea, tachycardia, hypoxia, oliguria, pulmonary oedema and respiratory failure following accidental exposure and poisoning of minoxidil. [Extracted from the article]

Reactions Weekly 13 Jul 2022 The table below provides a list of the drugs associated with non-serious adverse events identified in the scientific literature over the last week. [Extracted from the article]

However, in past (approximately four years after the initial onset of treatment), she had developed a mild, pustular-free, pruritic eruption on the scalp following topical application of an unknown minoxidil formulation, which was fully resolved within four days after the cessation of minoxidil application. The 48h and 72h readings showed: a positive reaction to minoxidil diluted in Trichofoam SP TM sp and minoxidil and estradiol diluted in Trichofoam SP TM sp . The alfatradiol/minoxidil/trichofoam was a compounded foam formulation containing 17-a-estradiol 0.05% and minoxidil 5% in Trichofoam SP TM sp . [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 16-year-old girl exhibited lack of efficacy during treatment with amiloride, amlodipine, labetalol, lisinopril and minoxidil for hypertension and potassium-chloride for hypokalaemia. The girl was noted to have hypertension and hypokalaemia while being evaluated for depression. However, a year later she presented for recurrent headaches, chronic persistent hypertension and persistent hypokalaemia (lack of efficacy). [Extracted from the article]

Based on clinical findings, a diagnosis of pityriasis amiantacea was made [ I duration of treatment to reaction onset not stated i ]. B » Editor comment: b A search of AdisBase, Medline and Embase did not reveal any previous case reports of pityriasis associated with minoxidil. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * First published case report A 47-year-old woman developed pityriasis amiantacea during treatment with minoxidil. [Extracted from the article]

The patients, who were scheduled to receive treatment with omeprazole, inadvertently received minoxidil as the master formulation sets contained minoxidil instead of omeprazole. Subsequently, they developed minoxidil therapy-related adverse events that included hypertrichosis (n=13), changes in hair color (n=2), diarrhoea (n=1), anxiety (n=1), severe asthenia (n=1), headache (n=1) or facial oedema(n=1). Thus assuming they are receiving treatment with omeprazole, the patients actually received treatment with oral minoxidil 4.5-20 mg/day for a duration of 5-120 days. [Extracted from the article]